KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Common Equity (2017 - 2025)

Historic Common Equity for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $456.1 million.

  • Twist Bioscience's Common Equity rose 3.38% to $456.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $456.1 million, marking a year-over-year increase of 3.38%. This contributed to the annual value of $473.0 million for FY2025, which is 5.69% up from last year.
  • As of Q4 2025, Twist Bioscience's Common Equity stood at $456.1 million, which was up 3.38% from $473.0 million recorded in Q3 2025.
  • In the past 5 years, Twist Bioscience's Common Equity registered a high of $863.4 million during Q1 2022, and its lowest value of $440.1 million during Q1 2025.
  • For the 5-year period, Twist Bioscience's Common Equity averaged around $602.7 million, with its median value being $600.2 million (2021).
  • As far as peak fluctuations go, Twist Bioscience's Common Equity soared by 13246.64% in 2021, and later plummeted by 2530.77% in 2024.
  • Over the past 5 years, Twist Bioscience's Common Equity (Quarter) stood at $626.2 million in 2021, then rose by 19.19% to $746.3 million in 2022, then fell by 20.94% to $590.0 million in 2023, then fell by 22.73% to $455.9 million in 2024, then grew by 0.03% to $456.1 million in 2025.
  • Its Common Equity stands at $456.1 million for Q4 2025, versus $473.0 million for Q3 2025 and $478.2 million for Q2 2025.